Type to search

Radiopharm Enters Into Strategic Collaboration With Lantheus and Assumes PD-L1 Licensing Agreement From Nanomab | Pharmtech Focus
RAD Adds Brain Tumor Technology to Portfolio | Pharmtech Focus
Diaprost Licenses its Novel Theranostic Antibody, hu5A10, to Radiopharm Theranostics for Development in the Treatment and Diagnosis of Prostate Cancer | Pharmtech Focus